Simulations PlusSLP +0.22%81 3-Year ROIIC % is -16.14 as of Aug. 2025. GuruFocus rates SLP with a GF Score™ of 81/100 and a GF Value™ of $38.31 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 619 Healthcare Providers & Services companies, Simulations Plus ranks worse than 73.67% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Simulations Plus's 3-Year ROIIC % for the quarter that ended in Aug. 2025 was -16.14%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Simulations Plus's 3-Year ROIIC % or its related term are showing as below:
SLP's 3-Year ROIIC % is ranked worse than 73.67% of 619
companies
in the Healthcare Providers & Services industry
Industry Median: 3.28
vs SLP: -16.14
Simulations Plus (NAS:SLP) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Simulations Plus 3-Year ROIIC % Related Terms
Simulations Plus 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Simulations Plus's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Simulations Plus's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simulations Plus 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Simulations Plus's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Simulations Plus's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Simulations Plus (SLP) has a 3-Year ROIIC % of -16.14 as of Aug. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Simulations Plus and its competitors. According to the industry distribution chart, Simulations Plus ranks #456 out of 619 companies in the Healthcare Providers & Services industry, placing it in the top 73.7%.
Is Simulations Plus' 3-Year ROIIC % too high?
Simulations Plus' current 3-Year ROIIC % is -16.14. Based on the distribution chart, Simulations Plus ranks #456 out of 619 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Simulations Plus has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' 3-Year ROIIC % compare to TBRG and CARL?
According to the Healthcare Providers & Services industry distribution chart, Simulations Plus ranks #456 out of 619 companies for 3-Year ROIIC %. This places Simulations Plus in the lower half of its industry. The industry median 3-Year ROIIC % is 3.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.28, based on 619 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Simulations Plus and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simulations Plus's current 3-Year ROIIC % is -16.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (SLP) is currently considered Significantly Undervalued. The stock's GF Value™ is $38.31, compared to a current price of $18.38 — trading 52% below its estimated fair value. The current 3-Year ROIIC % is -16.14. Simulations Plus' overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Simulations Plus (SLP), the current 3-Year ROIIC % is -16.14 as of Aug. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simulations Plus (SLP) Overvalued in 2026?
Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued.
The current stock price of $18.38 is trading 52% below its estimated GF Value™ of $38.31.
GuruFocus considers Simulations Plus to be Significantly Undervalued.
Key valuation signals for SLP:
3-Year ROIIC %: -16.14
GF Value™: $38.31 vs. price of $18.38 (52% below fair value)
No single metric tells the full story. See the SLP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
81GF Score
Get the complete analysis for SLP
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLP has been successfully added to your 
